胸腺五肽辅助治疗复治菌阳肺结核的效果及对呼吸功能、免疫功能的影响  

The effect of thymopentin in adjuvant treatment of retreatment of bacterium-positive pulmonary tuberculosis and its influence on respiratory function and immune function

作　　者：李影 刘大朋[2] LI Ying;LIU Da-peng(Department Three of Internal Medicine,Zaozhuang Tumor Hospital,Zaozhuang 277500,China)

机构地区：[1]山东省枣庄市肿瘤医院内三科,277500 [2]枣庄科技职业学院,277599

出　　处：《中国实用医药》2021年第20期10-13,共4页China Practical Medicine

摘　　要：目的探讨复治菌阳肺结核患者采用胸腺五肽辅助治的疗效及对其呼吸功能、免疫功能的影响。方法94例复治菌阳肺结核患者,以随机抽签法分为研究组与参照组,各47例。参照组以常规化疗方案开展治疗,研究组在常规方案基础上加用胸腺五肽辅助治疗。对比两组临床疗效、呼吸功能变化、免疫功能变化。结果治疗后,研究组3、6个月的痰菌转阴率分别为57.45%、91.49%,均高于参照组的36.17%、70.21%,差异有统计学意义(P<0.05)。治疗后,研究组的第1秒用力呼气容积占预计值的百分比(FEV1%)、用力肺活量占预计值的百分比(FVC%)及FEV1/FVC分别为(86.29±10.16)%、(89.24±8.16)%、(74.59±4.39)%,均高于参照组的(75.21±9.21)%、(80.31±8.31)%、(68.33±4.25)%,差异有统计学意义(P<0.05)。治疗后,研究组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平分别为(72.03±4.29)%、(39.17±4.55)%、(1.34±0.27),均高于参照组的(60.24±5.09)%、(25.89±4.01)%、(0.82±0.25),差异有统计学意义(P<0.05);两组CD8^(+)水平对比差异无统计学意义(P>0.05)。结论胸腺五肽用于复治菌阳肺结核辅助治疗疗效显著,可对患者的呼吸功能、免疫功能进行有效改善,且安全性较高,值得推广。Objective To discuss the efficacy of thymopentin in adjuvant treatment of retreatment of bacterium-positive pulmonary tuberculosis and its influence on respiratory function and immune function.Methods A total of 94 patients with retreatment of bacterium-positive pulmonary tuberculosis were divided into research group and reference group according to random lottery method,with 47 cases in each group.The reference group was treated with conventional chemotherapy,and the research group was treated with thymopentin based on conventional chemotherapy.The clinical efficacy,changes of respiratory function and immune function were compared between the two groups.Results After treatment,the sputum negative conversion rate after 3 months and 6 months of treatment of the research group were 57.45%and 91.49%,which were higher than 36.17%and 70.21%of the reference group,and the difference was statistically significant(P<0.05).After treatment,the forced expiratory volume in the first second as a percentage of the predicted value(FEV1%),forced vital capacity as a percentage of the predicted value(FVC%)and FEV1/FVC of the research group were(86.29±10.16)%,(89.24±8.16)%and(74.59±4.39)%,which were all higher than(75.21±9.21)%,(80.31±8.31)%and(68.33±4.25)%of the reference group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)of the research group were(72.03±4.29)%,(39.17±4.55)%and(1.34±0.27),which were all higher than(60.24±5.09)%,(25.89±4.01)%and(0.82±0.25)of the reference group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in CD8^(+)level between the two groups(P>0.05).Conclusion Thymopentin is effective in the adjuvant treatment of retreatment of bacterium-positive pulmonary tuberculosis,and it can effectively improve the respiratory function and immune function of patients.It is safe and worthy of promotion.

关 键 词：复治菌阳肺结核 胸腺五肽 辅助治疗 呼吸功能 免疫功能 临床疗效 

分 类 号：R521[医药卫生—内科学]